Companies: 10,795·Total market cap: $144.5T
Paratek Pharmaceuticals, Inc.

Paratek Pharmaceuticals, Inc.

PRTKNASDAQHealthcare
$2.23
+$0.04(+1.83%)
Market Cap$127828952
P/E Ratio—
52W High$3.65
52W Low$1.29
Overview

Paratek Pharmaceuticals, Inc. (PRTK) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

PRTK · net income · updated Jun 9, 2026

Core profitability metrics

Net income was −$63.6M for FY2022 (fiscal year ending 2022-12-31), down 7.6% year-over-year. Net profit margin was -42.2%. Based on available data, Paratek Pharmaceuticals, Inc. has been profitable since at least 2008.

FY2022 Net Income−$63.6M▼ -7.6% YoY
Trailing 12M (TTM)—trailing 4 quarters sum
Net Profit Margin-42.2%−$63.6M ÷ $150.8M
YoY Change-7.6%—
5-Year CAGRN/AN/A — contains loss years
FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0
Source: FMP /income-statement · US GAAP · USDUpdated: Jun 9, 2026

Annual net income history

Net IncomeNet LossNet Margin %★ First Profit: 2008

▸ FMP /income-statement · Annual · PRTK net income history · PRTK profit margin

Annual net income data

Fiscal YearNet IncomeYoY ChangeNet Margin
FY2022Loss−$63.6M▼ 7.6%-42.2%
FY2021Loss−$59.1M▲ +49.2%-48.9%
FY2020Loss−$116.3M▲ +9.7%-267.2%
FY2019Loss−$128.8M▼ 14.6%-778.5%
FY2018Loss−$112.4M▼ 26.1%-656.4%

Net income vs peers (Healthcare)

#CompanyNet IncomeYoY
#1
Johnson & Johnson
Johnson & Johnson
JNJ
$26.80B+90.6%#2
Eli Lilly and Company
Eli Lilly and Company
LLY
$20.64B+94.9%#3
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$12.06B-16.3%#4
AbbVie Inc.
AbbVie Inc.
ABBV
$4.23B-1.2%
Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Paratek Pharmaceuticals, Inc. (PRTK) reported net income of −$63.6M for FY2022 (fiscal year ending 2022-12-31), down 7.6% year-over-year. The net profit margin was -42.2% — meaning the company kept $-0.42 of every dollar of revenue as profit.

Based on available data, Paratek Pharmaceuticals, Inc. has been profitable since at least 2008. Net income reached a peak of $34.8M in FY2008. Data available for 15 fiscal years.

Paratek Pharmaceuticals, Inc.'s net profit margin was -42.2% for FY2022, based on the latest annual results.

Investors sometimes search for "Paratek Pharmaceuticals, Inc. net worth" — the company's market capitalization is a separate figure from PRTK net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.
RevenueFinancial statementsEarningsForecastPrice historyMarket capFree cash flow

Frequently asked questions

PRTK net income · 4 questions

Paratek Pharmaceuticals, Inc. is not currently profitable on an annual basis. The company reported a net loss of $63.6M for FY2022.

is PRTK profitabledoes PRTK make a profitPRTK profitabilityPRTK profitable company

▸ Source: FMP /income-statement · GAAP · Paratek Pharmaceuticals, Inc. · Paratek Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026